American Century Companies Inc. Has $8.44 Million Stock Position in OraSure Technologies, Inc. $OSUR

Key Points

• American Century Companies Inc. increased its stake in OraSure Technologies, Inc. by 6.8%, holding over 2.5 million shares worth approximately $8.4 million as of the latest filing.
• Various other institutional investors, including Private Management Group Inc. and D. E. Shaw & Co. Inc., have also significantly invested in OraSure Technologies, indicating strong institutional interest in the company.
• OraSure Technologies' stock price has fluctuated between a 12-month low of $2.36 and a high of $4.61, with a current trading price of $3.48 and an average analyst rating of "Hold" with a price target of $3.00.

American Century Companies Inc. increased its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 6.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,505,124 shares of the medical instruments supplier's stock after purchasing an additional 159,287 shares during the period. American Century Companies Inc. owned approximately 3.23% of OraSure Technologies worth $8,442,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in OSUR. Private Management Group Inc. acquired a new stake in OraSure Technologies during the 1st quarter worth approximately $14,886,000. Gagnon Securities LLC acquired a new stake in OraSure Technologies during the 1st quarter worth approximately $3,619,000. D. E. Shaw & Co. Inc. lifted its holdings in OraSure Technologies by 180.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier's stock worth $5,478,000 after purchasing an additional 976,475 shares during the last quarter. Gagnon Advisors LLC acquired a new stake in OraSure Technologies during the 1st quarter worth approximately $2,687,000. Finally, Systematic Financial Management LP lifted its holdings in OraSure Technologies by 33.7% during the 4th quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier's stock worth $6,042,000 after purchasing an additional 421,497 shares during the last quarter. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Trading Up 0.6%

NASDAQ OSUR traded up $0.02 during midday trading on Monday, hitting $3.31. The company had a trading volume of 747,291 shares, compared to its average volume of 623,367. The company has a market capitalization of $242.09 million, a PE ratio of -4.94 and a beta of 0.44. The firm has a 50-day moving average price of $3.08 and a 200-day moving average price of $3.09. OraSure Technologies, Inc. has a twelve month low of $2.36 and a twelve month high of $4.61.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on OSUR. Evercore ISI reissued an "in-line" rating and set a $3.00 price target on shares of OraSure Technologies in a report on Monday, May 19th. Wall Street Zen raised OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.